Grand Pharmaceutical Group (HKG:0512) has completed its phase III clinical trial of GPN00833 and met its clinical endpoint, a Monday bourse filing said.
GPN00833 is an anti-inflammatory and analgesic hormone nanosuspension eye drop.
The study showed a significantly higher percentage of patients with zero anterior chamber cell counts from the eighth to the 15th day post-surgery as compared to patients in the placebo group.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.